Trial · NCT01208103
Adverse events33
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 33
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anemia | Blood and lymphatic system disorders | Bevacizumab + Capecitabine + Oxaliplatin | 17 | 30 | |
| other | Platelet count decreased | Investigations | Bevacizumab + Capecitabine + Oxaliplatin | 14 | 30 | |
| other | Neutrophil count decreased | Investigations | Bevacizumab + Capecitabine + Oxaliplatin | 11 | 30 | |
| other | Abdominal pain | Gastrointestinal disorders | Bevacizumab + Capecitabine + Oxaliplatin | 7 | 30 | |
| other | Alanine aminotransferase increased | Investigations | Bevacizumab + Capecitabine + Oxaliplatin | 16 | 30 | |
| other | Alkaline phosphatase increased | Investigations | Bevacizumab + Capecitabine + Oxaliplatin | 7 | 30 | |
| other | Anorexia | Metabolism and nutrition disorders | Bevacizumab + Capecitabine + Oxaliplatin | 23 | 30 | |
| other | Ascites | Gastrointestinal disorders | Bevacizumab + Capecitabine + Oxaliplatin | 1 | 30 | |
| other | Aspartate | Investigations | Bevacizumab + Capecitabine + Oxaliplatin | 21 | 30 | |
| other | Blood bilirubin increased | Investigations | Bevacizumab + Capecitabine + Oxaliplatin | 6 | 30 | |
| other | Colitis | Gastrointestinal disorders | Bevacizumab + Capecitabine + Oxaliplatin | 1 | 30 | |
| other | Creatinine increased | Investigations | Bevacizumab + Capecitabine + Oxaliplatin | 2 | 30 | |
| other | Dehydration | Metabolism and nutrition disorders | Bevacizumab + Capecitabine + Oxaliplatin | 11 | 30 | |
| other | Diarrhea | Gastrointestinal disorders | Bevacizumab + Capecitabine + Oxaliplatin | 23 | 30 | |
| other | Dysesthesia | Nervous system disorders | Bevacizumab + Capecitabine + Oxaliplatin | 26 | 30 | |
| other | Fatigue | General disorders | Bevacizumab + Capecitabine + Oxaliplatin | 24 | 30 | |
| other | Headache | Nervous system disorders | Bevacizumab + Capecitabine + Oxaliplatin | 3 | 30 | |
| other | Hypertension | Vascular disorders | Bevacizumab + Capecitabine + Oxaliplatin | 11 | 30 | |
| other | Hyponatremia | Metabolism and nutrition disorders | Bevacizumab + Capecitabine + Oxaliplatin | 3 | 30 | |
| other | Nausea | Gastrointestinal disorders | Bevacizumab + Capecitabine + Oxaliplatin | 23 | 30 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01208103/events